Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy

Information

  • Patent Grant
  • 9039617
  • Patent Number
    9,039,617
  • Date Filed
    Tuesday, May 6, 2014
    10 years ago
  • Date Issued
    Tuesday, May 26, 2015
    9 years ago
Abstract
A method and system uniquely capable of generating thermal bubbles for improved ultrasound imaging and therapy. Several embodiments of the method and system contemplates the use of unfocused, focused, or defocused acoustic energy at variable spatial and/or temporal energy settings, in the range of about 1 kHz-100 MHz, and at variable tissue depths. The unique ability to customize acoustic energy output and target a particular region of interest makes possible highly accurate and precise thermal bubble formation. In an embodiment, the energy is acoustic energy. In other embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc.), or other energy forms, such radio frequency electric currents (including monopolar and bipolar radio-frequency current). In an embodiment, the energy is various combinations of acoustic energy, electromagnetic energy and other energy forms or energy absorbers such as cooling.
Description
FIELD OF INVENTION

Embodiments of the present invention generally relate to therapeutic treatment systems, and more particularly, to methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy.


BACKGROUND

Ultrasound has long been used for diagnostic imaging applications. More recently however, several new therapeutic applications for ultrasound are being discovered.


SUMMARY

Various embodiments of the present invention provide a method and system uniquely capable of generating thermal bubbles for improved ultrasound imaging and therapy.


In various embodiments, the physical mechanisms for generating thermal bubbles can comprise one or more of the following: (1) selective absorption of ultrasound energy within a bubbly medium due to enhanced attenuation from scattering; (2) enhanced thermal gradient in a micro-bubble rich region due to enhanced viscous losses from stable cavitation; (3) enhanced thermal response due to ultrasound-gas-vapor voids; and (4) enhanced deposition of thermal energy from inertial cavitation events.


In various embodiments, providing ultrasound energy to cell membranes or tissues with thermal bubbles ultrasound imaging and therapy. For example, in various embodiments, the permeability and/or transparency of cell membranes can be modulated. For example, in some embodiments, the permeability and/or transparency of cell membranes is increased. In some embodiments, heating can cause better diffusion of a material or a drug through the layers of skin tissue. Cavitation and radiation force involves sustained oscillatory motion of bubbles (a.k.a. stable cavitation) and/or rapid growth and collapse of bubbles (a.k.a. inertial cavitation). Resulting fluid velocities, shear forces and shock waves can disrupt cell membranes or tissues and induce chemical changes in the surrounding medium. The collapse of bubbles can additionally increase the bubble core temperature and induce chemical changes in the medium (e.g., generate highly reactive species, such as free radicals). Each of the above effects can impact ultrasound imaging and therapy effectiveness. In addition, other ways to impact ultrasound imaging and therapy include melting or mechanically disrupting thermally sensitive or mechanically fragile substances, such as medicant-carrying liposomes and/or other chemical loaded, gas or liquid filled stabilized spheres, analogous to local delivery.


In some embodiments, ultrasound imaging and therapy can be enhanced when shock waves generated upon collapse of bubbles disrupt the stratum corneum and thereby enhance skin permeability. Likewise, ultrasound imaging and therapy effectiveness can be enhanced when shock waves transiently compromise the integrity of cell membranes or tissues, or when local free-radical concentration enhances medicant toxicity. Moreover, certain medicants can be activated and/or released using energy. In that regard, a medicant encapsulated in a carrier can be released at the site of interest using energy (e.g., acoustic energy). For example, U.S. Pat. No. 6,623,430, entitled “Method and Apparatus for Safely Delivering Medicants to a Region of Tissue Using Imaging, Therapy and Temperature Monitoring Ultrasonic System”, which is hereby incorporated by reference in its entirety.


In various embodiments, a region of interest (or “ROI”) is located within one of the nonviable epidermis (i.e., the stratum corneum), the viable epidermis, the dermis, the subcutaneous connective tissue and fat, and the muscle. Depths may be in the range of about 0 mm to about 3 mm, 5 mm, 8 mm, 10 mm, 25 mm, 60 mm, 80 mm, or 100 mm or more. In accordance with various embodiments, the ROT is located about 20 mm to about 30 mm below the stratum corneum. Further, a plurality of ROI can be treated, and in some embodiments, simultaneously. For example, the ROI may consist of one or more organs or a combination of tissues either superficial or deep within the body.


In various embodiments, the method and system is uniquely capable of disrupting cell membranes or tissues and inducing chemical changes in the surrounding medium at either a single or multiple layers of skin tissue simultaneously (e.g., a plurality of depths within a cell membrane or tissue simultaneously). For example, in one embodiment, one frequency of acoustic energy at one skin layer might generate shock waves upon collapse of bubbles to disrupt the stratum corneum and thereby enhance skin permeability. A different frequency of acoustic energy at a different skin layer might simply provide heat to cause better diffusion of medicants through the layers of skin tissue. Yet another frequency of acoustic energy at a different skin layer might compromise the integrity of cell membranes or tissues, or generate local free-radicals to enhance or reduce medicant toxicity. In various embodiments, acoustic energy can be deposited in three-dimensions and at variable depths to selectively increase tissue permeability to thereby steer or guide the medicant through the tissue to a region of interest.


In various embodiments, the methods and systems disclosed herein contemplate the use of unfocused, focused, or defocused acoustic energy at variable spatial and/or temporal energy settings, in the range of about 1 kHz-100 MHz (e.g. about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 3 MHz-7 MHz, 1 MHz-20 MHz, 1 MHz-10 MHz, 10 MHz-50 MHz, and/or 50 MHz-100 MHz, and any ranges or combinations of ranges), and at variable tissue depths. In various embodiments, the tissue depth can include, but are not limited to, 0-1 mm, 1 mm-2 mm, 2 mm-3 mm, 3 mm-4 mm, 4 mm-5 mm, 5 mm-6 mm, 6 mm-7 mm, 7 mm-8 mm, and 8 mm or more, and any ranges or combinations of ranges. The unique ability to customize acoustic energy output and target a particular region of interest makes possible highly accurate and precise thermal bubble formation.


In various embodiments, a system comprises a probe, a control system, and a display or indicator system. The probe can comprise various probe and/or transducer configurations, In various embodiments, the probe delivers unfocused, focused, or defocused ultrasound energy to the region of interest. Imaging and/or monitoring may alternatively be coupled and/or co-housed with a system contemplated by embodiments of the present invention.


In various embodiments, the control system and display system can also optionally comprise various configurations for controlling probe and system functionality, including for example, a microprocessor with software and a plurality of input/output devices, a system for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems fir monitoring, systems for sensing the spatial position of the probe and/or transducers, and systems for handling user input and recording treatment results, among others.


In various embodiments, a system for generating thermal bubbles for improved ultrasound imaging and therapy includes a control system configured for control of the system, a probe configured for generating thermal bubbles, and a display system.


In various embodiments, a system for imaging thermal bubbles includes a control system configured for control of the system, a probe configured for imaging thermal bubbles, and a display system.


In various embodiments, a method for generating thermal bubbles for improved ultrasound imaging and therapy includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest, and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz.


In various embodiments, a method for generating thermal bubbles to evoke a cellular response includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest; and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz (e.g., about 10 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz or overlapping ranges therein), and evoking a cellular response. In various embodiments the cellular response comprises one or more of a wound healing response, an immune histological response, heat-shock protein expression, programmed cell death, wound debridement, keloid/scar healing, and increased localized micro-circulation.


In various embodiments, a method for generating thermal bubbles to affect a chemical moiety includes the steps of providing a source of acoustic energy, coupling the acoustic energy to a region of interest; and focusing the acoustic energy to the region of interest to generate thermal bubbles, wherein the source frequency of the acoustic energy is in the range of about 10 kHz to about 30 MHz (e.g., about 10 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz, or overlapping ranges therein) and evoking an effect on a chemical moiety. In various embodiments, the effect includes enhancing the delivery or augmenting the activation of the chemical moiety.


In various embodiments, a method for optimization of therapy includes concomitant monitoring of bubble activity by monitoring (a) one or more non-thermal responses, (b) one or more thermal responses and/or (c) one or more tissue property changes.


In several embodiments, the systems (and methods thereof) comprise the use of thermal bubbles in which the source frequency of the acoustic energy is about 1-10 MHz for therapy (e.g., 4 or 7 MHz) and 5-25 MHz for imaging (e.g., 18 MHz).





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of various embodiments of the invention is particularly pointed out in the claims. Various embodiments of the invention, both as to organization and method of operation, may be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals, and:



FIG. 1 illustrates a block diagram of a method for generating thermal bubbles for improved ultrasound imaging and therapy in accordance with various embodiments of the present invention;



FIG. 2 illustrates a schematic diagram of a treatment system configured to generate thermal bubbles in accordance with an various embodiments of the present invention;



FIG. 3 illustrates a block diagram of a treatment system in accordance with various embodiments of the present invention;



FIGS. 4A, 4B, 4C, 4D, and 4E illustrate cross-sectional diagrams of an transducer used in a system in accordance with various embodiments of the present invention, and



FIGS. 5A, 5B, and 5C illustrate block diagrams of a control system used in a system in accordance with various embodiments of the present invention.





DETAILED DESCRIPTION

Several embodiments of the present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions and processes. For example, various embodiments of the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions and processes under the control of one or more control systems or other control devices. In addition, various embodiments of the present invention may be practiced in any number of medical contexts and the embodiments relating to a method and system for generating thermal bubbles for improved ultrasound imaging and therapy, as described herein, are merely indicative of embodiments of applications for the invention. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of embodiments of the present invention may be suitably applied to other applications.


In various embodiments of systems, and as illustrated in FIG. 1, the physical mechanisms for generating thermal bubbles can comprise: (1) selective absorption of ultrasound energy within a bubbly medium due to enhanced attenuation from scattering; (2) enhanced thermal gradient in a micro-bubble rich region due to enhanced viscous losses from stable cavitation; (3) enhanced thermal response due to ultrasound-gas-vapor voids; and/or (4) enhanced deposition of thermal energy from inertial cavitation events.


Each one of these mechanisms can be modulated either individually or used in combination with a thermal tissue effect. In various embodiments, the source frequency is between 1 kHz-100 MHz, 5 kHz-50 MHz, and/or 10 kHz-30 MHz (e.g., about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, and/or 10 MHz-30 MHz, or overlapping ranges therein).


In various embodiments, the activation source powers are dependent on the frequency, bubble size distribution, bubble density and tissue. For example, in some embodiments, the lower the frequency, the less intense field is required to initiate thermal bubble activity. In some embodiments, the higher the nominal bubble size, the lower the source frequency at which the gas bodies will resonate. In some embodiments, the higher the local concentration of gas bodies, the greater effect with thermal bubbles can be achieved.


A wide range of transducer design configurations are used in accordance with several embodiments, as further discussed below. These thermal bubble effects can also be leveraged to augmented imaging and treatment monitoring.


The methods and systems according to several embodiments disclosed herein contemplate the use of unfocused, focused, or defocused acoustic energy at variable spatial and/or temporal energy settings, in the range of about 1 kHz-100 MHz (e.g., about 1 kHz-50 kHz, 50 kHz-100 kHz, 100 kHz-500 kHz, 500 kHz-1 MHz, 1 MHz-10 MHz, 10 MHz-30 MHz, and/or 30 MHz-100 MHz, or overlapping ranges therein), and at variable tissue depths. The unique ability to customize acoustic energy output and target a particular region of interest makes possible highly accurate and precise thermal bubble formation.


In several embodiments, the energy is acoustic energy. In other embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc., or combinations thereof), or other energy forms, such radio frequency electric currents (including monopolar and bipolar radio-frequency current). In an embodiment, the energy is various combinations of acoustic energy, photon based energy, electromagnetic energy and other energy forms or energy absorbers such as cooling.


One or more of a transducer and/or transduction element configuration, a lens, and mechanical movement of a transducer may facilitate targeting of a particular region of interest and/or thermal bubble formation at specific locations.


In accordance with a method according to several embodiments, thermal bubbles act as contrast agents (e.g., markers or boundaries) for ultrasound imaging and therapy. In this manner, a region of interest can be marked or defined such that acoustic energy can be locally applied at for example, a cell, tissue, gland, fiber, or tumor. A boundary can be in any two-dimensional or three-dimensional configuration suitable for defining a region of interest for acoustic energy deposition (e.g., circle, square, triangle, sphere, cube, cone, or any arbitrary shape). The acoustic energy deposited therein may be for any therapeutic purpose now known or later devised (e.g., for ablative or non-ablative purposes).


In accordance with another method, just as thermal bubbles are used as boundaries for acoustic energy inclusion, as described herein, thermal bubbles can be used as boundaries for acoustic energy exclusion. In other words, thermal bubbles can be used to protect or to avoid various cells, tissues, glands, fibers, and/or regions of even higher acoustic impedance or sensitivity, for example. In some embodiments, bubbles are used to partially or fully isolate a region of interest.


Because thermal bubbles exhibit high acoustic impedance, in accordance with some embodiments of a method, they are used to concentrate acoustic energy deposition within a region of interest. For example, thermal bubbles may be created in such a manner so as to “funnel” acoustic energy as it moves from the energy source to the region of interest, thereby concentrating acoustic energy at the deposition site. An acoustical impedance mismatch can be created between the thermal bubble and the surround tissue. This acoustical mismatch can cause acoustic energy traveling through tissue to reflect, deflect, and/or scatter upon contact with the thermal bubble.


In various embodiments, a method of providing non-invasive ultrasound treatment, can comprise coupling an acoustic source to a surface of skin; providing a first acoustic energy into a region of interest below the surface; creating thermal bubbles in a first portion of the region of interest; providing a second acoustic energy into a second portion of the region of interest; and stimulating a bio-effect in the second portion of the region of interest.


In one embodiment, the method can comprise forming a boundary comprising the thermal bubbles. In one embodiment, the method can comprise reflecting a portion of the second acoustic energy off of at least one of the thermal bubbles. In one embodiment, the method can comprise directing the portion of the second portion of the second acoustic energy away from tissue outside of the region of interest from the second acoustic energy. In one embodiment, the method can comprise protecting the tissue outside of the region of interest from the second acoustic energy. In one embodiment, the tissue outside of the region of interest comprises an internal organ. In one embodiment, the method can comprise directing the portion of the second portion of the second acoustic energy into the second portion of the region of interest.


In one embodiment, the method can comprise scattering at least a portion of the second acoustic energy. In one embodiment, the method can comprise concentrating the second acoustic energy into the second portion of the region of interest. In one embodiment, the method can comprise controlling a size of the thermal bubbles. In one embodiment, the method can comprise increasing a temperature of the first portion of the region of interest. In one embodiment, the method can comprise controlling a size of the thermal bubbles. In one embodiment, the method can comprise surrounding the second portion of the region of interest with the boundary.


In one embodiment, the method can comprise creating a thermal lesion in the second portion of the region of interest. In one embodiment, the method can comprise cosmetically enhancing the skin. In one embodiment, the method can comprise treating the region of interest. In one embodiment, the method the stimulating a bio-effect in the second portion of the region of interest is reducing a volume of tissue. In one embodiment, the method can comprise tightening a portion of the surface of the skin. In one embodiment, the method can comprise providing a third acoustic energy to region of interest. In one embodiment, the method can comprise stimulating a second bio-effect in the region of interest.


In various embodiments, a method of cosmetic enhancement can comprise coupling at least one source to a region of interest; directing a first energy into the region of interest; creating a plurality of thermal bubbles in at least one of the region of interest and a non-target region; directing a second energy into the region of interest; and enhancing at least a portion of the region of interest.


In one embodiment, the at least one source comprises an ultrasound source and a pulsed laser. In one embodiment, the first energy is at least one of photon based energy and ultrasound energy. In one embodiment, the second energy is at least one of photon based energy and ultrasound energy. In one embodiment, the method can further comprise ablating tissue in the region of interest.


In one embodiment, the method can comprise tightening skin on a surface of the region of interest. In one embodiment, the method can comprise introducing a chemical moiety configured to enhance the creating the plurality of thermal bubbles. In one embodiment, the method can comprise imaging at least a portion of the region of interest. In one embodiment, the method can comprise locating the plurality of thermal bubbles. In one embodiment, the method can comprise reflecting the second energy off of at least one of the thermal bubbles.


In various embodiments, a method of treating tissue can comprise providing a first energy into a region of interest; creating at least one thermal bubble in the region of interest; providing a second energy into the region of interest; modulating the second energy; and controlling a size of the at least one thermal bubble.


In one embodiment, the method can comprise increasing the size of the at least one thermal bubble. In one embodiment, the method can comprise oscillating between a first size and a second size of the at least one thermal bubble. In one embodiment, the method can comprise stimulating a bio-effect in the region of interest. In one embodiment, the method can comprise inserting a plurality of bubbles into the region of interest. In one embodiment, the method can comprise increasing a temperature within the region of interest. In one embodiment, the method can comprise stimulating a therapeutic effect within the region of interest. In one embodiment, the method can comprise providing a third energy into the region of interest. In one embodiment, the method can comprise thermally injuring a portion of tissue in the region of interest. In one embodiment, the method can comprise cosmetically enhancing at least a portion of the region of interest.


In accordance with some methods, thermal bubbles are also particularly useful in preferential heating applications. For example, various cells, tissues, glands, fibers, and tumors can be either directly or indirectly therapeutically benefited by increases in temperature. And various therapeutic treatments, such as drug delivery, are facilitated by increases in temperature. Heating applications may be carried out alone or in combination with other thermal bubble applications and/or ultrasound imaging or therapy.


As mentioned above, collapse of cavitation bubbles can generate shock waves capable of disrupting cells and tissues and can induce chemical changes in the surrounding medium (e.g., generate highly reactive species, such as free radicals). Because some embodiments of the present invention enable highly accurate and precise thermal bubble formation, cells, tissues, glands, fibers, tumors, etc, can be selectively disrupted to accomplish various therapeutic applications, and various chemical changes can be induced at specific locations.


As noted above, each one of the abovementioned thermal bubble mechanisms can be modulated either individually or used in combination with a thermal tissue effect. In various embodiments, the combination effect of thermal tissue effects with the use of thermal bubbles effectuates and/or modulates a tissue response. In embodiments, use of bubble effects (inter-intracellular shear with a thermal tissue effect, e.g., thermal gradient), activates a wound healing response, an immune histological response, heat-shock protein expression and/or programmed cell death. In embodiments, tissue responses comprise wound debridement, keloid/scar healing, and increased localized micro-circulation.


In some embodiments, the thermal bubble response is maximized with the concomitant use of micro-bubble based formulations, emulsifiers, saponificants and/or emulsions. Thermal bubble use with other chemical moieties (e.g., analgesics, topical anesthetics, antibiotics, antibacterials, antimicrobials retinoids, etc.) may be useful to (1) enhance their delivery and/or (2) to augment their activation.


In some embodiments, selective tissue effects are achieved with a selective thermal-bubble response within one or more tissues (such as deep dermis, subcutaneous layers, etc). In other embodiments, selective tissue responses are enhanced within one or more glandular structures (such as sebaceous gland, sweat gland, hair follicle, etc.), by initiating a localized resonant cavity effect.


In accordance with some embodiments, optimization of therapy is accomplished using concomitant monitoring of bubble activity, for example, monitoring (a) one or more non-thermal responses (e.g., shear, inertial cavitation), (b) one or more thermal responses (e.g., vaporization) and/or (c) one or more tissue property changes. In accordance with one aspect of an embodiment, monitoring of bubble activity comprises imaging.


In various embodiments, the methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy comprise delivering energy to a region of interest (“ROI”) within one or more layers of tissue. As mentioned above, in an embodiment, the energy is acoustic energy. In other embodiments, the energy is photon based energy (e.g., IPL, LED, laser, white light, etc.), or other energy forms, such radio frequency electric currents (including monopolar and bipolar radio-frequency current). In an embodiment, the energy is various combinations of acoustic energy, photon-based energy, electromagnetic energy and other energy forms or energy absorbers such as cooling.


In various embodiments, systems and/or methods are configured to produce one or more bio-effects. The term “bio-effects”, as used herein, shall be given its ordinary meaning and shall also mean biological effects and include, but not be limited to, effects on tissue (including in vivo, in vitro, in situ and ex vivo tissue), cells, organs and other body parts. Bio-effects include, but are not limited to, incapacitating, partially incapacitating, severing, rejuvenating, removing, ablating, micro-ablating, shortening, manipulating, or removing tissue either instantly or over time, and/or other effects, and/or combinations thereof. Bio-effects include, but are not limited to, tissue manipulation to e.g., facilitate aesthetic effects. Bio-effects also include, but are not limited to, tissue manipulation to e.g., enhance collagen formation or healing. Various bio-effects are further disclosed in U.S. patent application Ser. No. 11/857,989 filed Sep. 19, 2007, published as US2008/0071255, which is incorporated in its entirety by reference, herein. In various embodiments, treatment of a specific subcutaneous tissue to achieve a desired bio-effect uses ultrasound energy from system that may be directed to a specific depth within ROI to reach the targeted subcutaneous tissue. In one embodiment, a bio-effect is cutting tissue. In one embodiment, for example, if it is desired to cut muscle (by applying ultrasound energy at ablative levels), which is a distance below the surface of the skin, ultrasound energy from ultrasound system may be provided at ROI at a level to reach above, below, or approximately at the distance targeted at an ablative level which may be capable of ablating muscle.


In various embodiments, bio-effects may produce a clinical outcome such as a brow lift which can comprise elevating the patient's eyebrows and reducing wrinkles on the patient's brow or forehead region. In some embodiments, the clinical outcome may be the same or similar to traditional invasive surgery techniques, and may comprise the removal of wrinkles through a brow lift or replacement of treatment muscles and/or other tissue and subcutaneous tissue within the forehead (or other regions on the body) with muscle relaxant drugs.


In various embodiments, wrinkles can be partially or completely removed by applying ultrasound energy at ROI along the patient's forehead at levels causing the desired bio-effects. In various embodiments, bio-effects can comprise ablating, micro-ablating, coagulating, severing, partially incapacitating, shortening, removing, or otherwise manipulating tissue or subcutaneous tissue to achieve the desired effect. In various embodiments, method can be used to ablate, micro-ablate, or coagulate a specific tissue, or can be used as part of removing the subcutaneous tissue. Further, in one embodiment, muscle (such as the corrugator supercilii muscle) can be paralyzed and permanently disabled.


In various embodiments, systems and/or methods are configured to initiate and/or stimulate one or more biological responses. In various embodiments, biological responses can comprise, but are not limited to, diathermy, hemostasis, revascularization, angiogenesis, growth of interconnective tissue, tissue reformation, ablation of existing tissue, protein synthesis and/or enhanced cell permeability. Two or more of these biological responses may be combined to facilitate rejuvenation and/or treatment of superficial tissue. In various embodiments, responses to embodiments of systems or embodiments of methods are initiated and/or stimulated by effects can include any biological response initiated and/or stimulated by energy effects, such as, for example: 1) hemostasis, including that stimulated from concentrated ultrasound, 2) subsequent revascularization/angiogenesis, such as that generated from high frequency applications of approximately 2 MHz to 7 MHz or more, 3) growth of interconnective tissue, 4) reformation and/or ablation of existing tissue such as fat, collagen and others, 5) increased cell permeability that may facilitate the possibility of stimulated gene or medication therapy to tissue, and/or increased permeability of certain tissues to a variety of medications initiated by ultrasound frequencies 10 kHz to 10 MHz, 6) enhanced delivery and/or activation of medicants, 7) stimulation of protein synthesis and/or 8) any other possible tissue response such as coagulative necrosis. Thus, for example, in various embodiments, a low intensity dispersed ultrasound field can be generated to provide for angiogenesis, an increased intensity homogeneous or uniform ultrasound field can be generated to provide for diathermy that increases the rate of healing and rejuvenation, and/or high intensity focused and/or unfocused beams can be generated to provide for temporary ablative and hemostatic effects in a variety of depth and positions of human tissue, whereby a summation or a combined effect of rejuvenation is created by combining ultrasound energy fields.


With reference to FIG. 1, in various embodiments, ROI 12 is located within one of the nonviable epidermis (i.e., the stratum corneum), the viable epidermis, the viable dermis, the subcutaneous connective tissue and fat, and the muscle. Further, while only ROI 12 is illustrated, a plurality of ROIs can be treated, and in some embodiments, treated simultaneously. For example, ROI 12 may consist of or comprise of one or more organs or a combination of tissues or subcutaneous tissues, which are either superficial or located deep within the body.


In an embodiment, with reference to FIG. 2, an ultrasound system 14, comprising a control system 20, a probe 18, and a display system 22, is used to deliver first energy 4 and second energy 6 to at least a portion of ROI 12, such as, for example one or more of stratum corneum 85, viable epidermis 86, viable dermis 88, subcutaneous connective tissue and fat 82, and muscle 84. In various embodiments, at least one of first energy 4 and second energy 6 is provided by an acoustic transducer. In one embodiment, first energy 4 and second energy 6 are two different forms of ultrasound energy.


With continued reference to FIG. 2, in various embodiments, a probe 18 is a transducer that delivers first energy 4 and second energy 6 to ROI 12. Either or both of first energy 4 and second energy 6 may be used to produce thermal bubbles 8 or provide ultrasound imaging or therapy. For example, acoustic energy 4 might create a thermal bubble 8 marker or boundary, or “funnel,” while acoustic energy 6 provides ultrasound therapy directed to the marker or within the boundary.


In an embodiment, suction is used to attach probe 18 to the patient's body. In this embodiment, a negative pressure differential is created, which enables, probe 18 to attach to stratum corneum 85 by suction. A vacuum-type device can be used to create the suction and the vacuum device can be integral with, detachably connected to, or completely separate from probe 18. Using suction to attach probe 18 to stratum corneum 85 I ensures that probe 18 is properly coupled to stratum corneum 85. Further, using suction to attach probe 18 also reduces the thickness of the tissue to make it easier to reach distinct layers of tissue.


Turning now to the embodiments illustrated in FIG. 3, a system 14 may be capable of emitting ultrasound energy that is focused, unfocused or defocused to treat skin and/or subcutaneous tissue within ROI 12. System 14 may comprise a probe 18, a control system 20, and a display 22. System 14 may be used to delivery energy to, and/or monitor, ROI 12.


With reference to FIGS. 4A-4E, illustrates various embodiments of an acoustic transducer 19 capable of emitting ultrasound energy. This may heat ROI 12 at a specific depth to target a specific tissue or subcutaneous tissue causing that tissue to be ablated, micro-ablated, coagulated, incapacitated, partially incapacitated, rejuvenated, shortened, paralyzed, or removed.


A coupling gel may be used to couple probe 18 to ROI 12 at a surface of stratum corneum 85, for example, a surface of a patient's skin. Ultrasound energy may be emitted in various energy fields in this embodiment. With additional reference to FIG. 4A and FIG. 4B and in this embodiment, the energy fields may be focused, defocused, and/or made substantially planar by transducer 19, to provide many different effects. Energy may be applied in a C-plane or C-scan. For example, in one embodiment, a substantially planar energy field may provide a heating and/or pretreatment effect, a focused energy field may provide a more concentrated source of heat or hypothermal effect, and a non-focused energy field may provide diffused heating effects. It should be noted that the term “non-focused” as used throughout encompasses energy that is unfocused or defocused.


In another embodiment, a transducer 19 may be capable of emitting ultrasound energy for imaging or treatment or combinations thereof. In an embodiment, transducer 19 may be configured to emit ultrasound energy at specific depths in ROI 12 to target a specific tissue. In this embodiment, transducer 19 may be capable of emitting unfocused or defocused ultrasound energy over a wide area in and/or around ROI 12 for treatment purposes.


In various embodiments, a transducer 19 may comprise one or more transduction elements 26 for facilitating treatment. Transducer 19 may further comprise one or more transduction elements 26, such as, for example, elements 26A and 26B as illustrated in FIGS. 4A and 4B. One or more transduction elements 26 may comprise piezoelectrically active material, such as lead zirconate titanate (PZT), or other piezoelectrically active material such as, but not limited to, a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, one or more transduction elements 26 may comprise any other materials configured for generating radiation and/or acoustical energy. Transducer 19 may also comprise one or more matching and/or backing layers coupled to the piezoelectrically active material of the one or more transduction elements 26. Transducer 19 may also be configured with single or multiple damping elements along the one or more transduction element 26.


In an embodiment, the thickness of the transduction element 26 of transducer 19 may be configured to be uniform. That is, the transduction element 26 may be configured to have a thickness that is generally substantially the same throughout.


In another embodiment, the transduction element 26 may also be configured with a variable thickness, and/or as a multiple damped device. For example, the transduction element 26 of transducer 19 may be configured to have a first thickness selected to provide a center operating frequency of a lower range, for example from approximately 1 kHz to 3 MHz. The transduction element 26 may also be configured with a second thickness selected to provide a center operating frequency of a higher range, for example from approximately 3 to 100 MHz or more.


In yet another embodiment, transducer 19 may be configured as a single broadband transducer excited with two or more frequencies to provide an adequate output for raising the temperature within ROI 12 to the desired level. Transducer 19 may also be configured as two or more individual transducers, wherein each transducer 19 may comprise a transduction element 26. The thickness of the transduction elements 26 may be configured to provide center-operating frequencies in a desired treatment range. For example, in an embodiment, transducer 19 may comprise a first transducer 19 configured with a first transduction element 26A having a thickness corresponding to a center frequency range of approximately 1 MHz to 3 MHz, and a second transducer 19 configured with a second transduction element 26B having a thickness corresponding to a center frequency of approximately 3 MHz to 100 MHz or more. Various other ranges of thickness for a first and/or second transduction element 26 can also be realized.


Moreover, in an embodiment, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the energy field. For example, with reference to the embodiments depicted in FIGS. 4A and 4B, transducer 19 may also be configured with an electronic focusing array 24 in combination with one or more transduction elements 26 to facilitate increased flexibility in treating ROI 12. Focusing array 24 may be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T1, T2, T3 1. By the term “operated,” the electronic apertures of array 24 may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations may be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 12.


In various embodiments, transduction elements 26 may be configured to be concave, convex, and/or planar. For example, in the embodiment illustrated in FIG. 4A, transduction elements 26A and 26B are configured to be concave in order to provide focused energy for treatment within at least a portion of ROI 12. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled “System and Method for Variable Depth Ultrasound Treatment,” incorporated herein by reference in its entirety.


In another embodiment, as illustrated in FIG. 4B, transduction elements 26A and 26B may be configured to be substantially flat in order to provide substantially uniform energy to RO 12. While FIGS. 4A and 41 illustrate embodiments with transduction elements 26 configured as concave and substantially flat, respectively, transduction elements 26 may be configured to be concave, convex, and/or substantially flat. In addition, transduction elements 26 may be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element 26 may be configured to be concave, while a second transduction element 26 may be configured to be substantially flat.


Moreover, transduction element 26 can be any distance from the patient's skin. In that regard, it can be far away from the skin disposed within a long transducer or it can be just a few millimeters from the surface of the patient's skin. In certain embodiments, the transduction element 26 can be positioned closer to the surface of a patient's skin when emitting ultrasound at high frequencies. Moreover, both three and two dimensional arrays of elements can be used in the present invention.


With reference to FIGS. 4C and 4D, transducer 19 may also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, in an embodiment, an annular array 28 may comprise a plurality of rings 30, 32, 34 to N. Rings 30, 32, 34 to N may be mechanically and electrically isolated into a set of individual elements, and may create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, T1, T2, T3 . . . TN. An electronic focus may be suitably moved along various depth positions, and may enable variable strength or beam tightness, while an electronic defocus may have varying amounts of defocusing. In an embodiment, a lens and/or convex or concave shaped annular array 28 may also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of annular array 28 in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within ROI 12.


With reference to FIG. 4E, another embodiment of a transducer 19 can be configured to comprise a spherically focused single element 36, annular/multi-element 38, annular with imaging region(s) 40, line-focused single element 42, 1-D linear array 44, 1-D curved (convex/concave) linear array 46, and/or 2-D array 48, combined with mechanical focus 50, convex lens focus 52, concave lens focus 54, compound/multiple lens focused 56, and/or planar array form 58 to achieve focused, unfocused, or defocused sound fields for at least one of imaging and therapy.


Transducer 19 may further comprise a reflective surface, tip, or area at the end of the transducer 19 that emits ultrasound energy. This reflective surface may enhance, magnify, or otherwise change ultrasound energy emitted from system 14.


In various embodiments, a probe 18 may be suitably controlled and operated in various manners by control system 20 as illustrated in FIGS. 2, 3 and 5A-5C which processes and sends one or more images obtained by transducer 19 to display 22. In the embodiment illustrated in FIGS. 5A-5C: control system 20 may be capable of coordination and control of the entire treatment process to achieve the desired effect on tissue within ROI 12. For example, in an embodiment, control system 20 may comprise power source components 60, sensing and monitoring components 62, cooling and coupling controls 64, and/or processing and control logic components 66. Control system 20 may be configured and optimized in a variety of ways with more or less subsystems and components to implement the system 14 for controlled targeting of the desired tissue in ROI 12.


For example, in various embodiments of power sourcing components 60, control system 20 may comprise one or more direct current (DC) power supplies 68 capable of providing electrical energy for the entire control system 20, including power required by a transducer electronic amplifier/driver 70. A DC current sense device 72 may also be provided to confirm the level of power entering amplifiers/drivers 70 for safety and monitoring purposes, among others.


In an embodiment, amplifiers/drivers 70 may comprise multi-channel or single channel power amplifiers and/or drivers. In an embodiment for transducer array configurations, amplifiers/drivers 70 may also be configured with a beamformer to facilitate array focusing. In various embodiments, a beamformer may be electrically excited by an oscillator/digitally controlled waveform synthesizer 74 with related switching logic.


Power sourcing components 60 may also comprise various filtering configurations 76. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver 70 to increase the drive efficiency and effectiveness. Power detection components 78 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components 78 may be used to monitor the amount of power entering probe 18.


Various sensing and monitoring components 62 may also be suitably implemented within control system 20. For example, in an embodiment, monitoring, sensing, and interface control components 80 may be capable of operating with various motion detection systems implemented within probe 18, to receive and process information such as acoustic or other spatial and temporal information from ROI 12. Sensing and monitoring components 62 may also comprise various controls, interfacing, and switches 82 and/or power detectors 78. Such sensing and monitoring components 62 may facilitate open-loop and/or closed-loop feedback systems within treatment system 14.


In an embodiment, sensing and monitoring components 62 may further comprise a sensor that may be connected to an audio or visual alarm system to prevent overuse of system 14. In this embodiment, the sensor may be capable of sensing the amount of energy transferred to the skin, and/or the time that system 14 has been actively emitting energy. When a certain time or temperature threshold has been reached, the alarm may sound an audible alarm, or cause a visual indicator to activate to alert the user that a threshold has been reached. This may prevent overuse of the system 14. In an embodiment, the sensor may be operatively connected to control system 20 and force control system 20, to stop emitting ultrasound energy from transducer 19.


In an embodiment, a cooling/coupling control system 84 may be provided, and may be capable of removing waste heat from probe 18. Furthermore the cooling/coupling control system 84 may be capable of providing a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from probe 18 to ROI 12. Such cooling/coupling control systems 84 can also be capable of operating in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.


Additionally, in various embodiments, an control system 20 may further comprise a system processor and various digital control logic 86, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays, computer boards, and associated components, including firmware and control software 88, which may be capable of interfacing with user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software 88 may be capable of controlling all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches 90 may also be suitably configured to control operation.


With reference to FIG. 5C, in various embodiments, a transducer 19 may be controlled and operated in various manners by a hand-held format control system 92. An external battery charger 94 can be used with rechargeable-type batteries 96 or the batteries can be single-use disposable types, such as AA-sized cells, Power converters 98 produce voltages suitable for powering a driver/feedback circuit 100 with tuning network 102 driving transducer 19 which is coupled to the patient via one or more acoustic coupling caps 104. Cap 104 can be composed of at least one of a solid media, semi-solid e.g. gelatinous media, and/or liquid media equivalent to an acoustic coupling agent (contained within a housing). Cap 104 is coupled to the patient with an acoustic coupling agent 106. In addition, a microcontroller and timing circuits 108 with associated software and algorithms provide control and user interfacing via a display 110, oscillator 112, and other input/output controls 114 such as switches and audio devices. A storage element 116, such as an Electrically Erasable Programmable Read-Only Memory (“EEPROM”), secure EEPROM, tamper-proof EEPROM, or similar device holds calibration and usage data. A motion mechanism with feedback 118 can be suitably controlled to scan the transducer 19, if desirable, in a line or two-dimensional pattern and/or with variable depth. Other feedback controls comprise a capacitive, acoustic, or other coupling detection means and/or limiting controls 120 and thermal sensor 122. A combination of the secure EEPROM with at least one of coupling caps 104, transducer 19, thermal sensor 122, coupling detectors, or tuning network. Finally, a transducer can further comprise a disposable tip 124 that can be disposed of after contacting a patient and replaced for sanitary reasons.


With reference again to FIGS. 2, 3, and 5, in various embodiments, a system 14 also may comprise display 22 capable of providing images of ROI 12 in certain embodiments where ultrasound energy may be emitted from transducer 19 in a manner suitable for imaging. In an embodiment, display 22 is a computer monitor. Display 22 may be capable of enabling the user to facilitate localization of the treatment area and surrounding structures, e.g., identification of subcutaneous tissue and/or internal organs. In an alternative embodiment, the user may know the location of the specific target below a skin surface, which is to be treated. After localization, ultrasound energy is delivered at a depth, distribution, timing, and energy level to achieve the desired effect within ROI 12. Before, during and/or after delivery of ultrasound energy, monitoring of the treatment area and surrounding structures may be conducted to further plan and assess the results and/or provide feedback to control system 20, and to a system operator via display 22. In an embodiment, localization may be facilitated through ultrasound imaging that may be used to define the position of a target within ROI 12.


In various embodiments, for ultrasound energy delivery, transducer 19 may be mechanically and/or electronically scanned to place treatment zones over an extended area in ROI 12. A treatment depth may be adjusted between a range of approximately 1 to 30 millimeters, or any other depth described herein. Such delivery of energy may occur through imaging of the target, within ROI 12 and then applying ultrasound energy at known depths over an extended area without initial or ongoing imaging.


In various embodiments, the ultrasound beam from transducer 19 may be spatially and/or temporally controlled at least in part by changing the spatial parameters of transducer 19, such as the placement, distance, treatment depth and transducer 19 structure, as well as by changing the temporal parameters of transducer 19, such as the frequency, drive amplitude, and timing, with such control handled via control system 20. Such spatial and temporal parameters may also be suitably monitored and/or utilized in open-loop and/or closed-loop feedback systems within ultrasound system 14.


Finally, it should be noted that while this disclosure is directed primarily to using ultrasound energy to conduct procedures non-invasively, that the method and system described above can also utilize energy such as ultrasound energy to assist in invasive procedures. For example, ultrasound energy can be used to ablate tissues during an invasive procedure. In this regard, ultrasound energy can be used for invasive and minimally invasive procedures.


The present invention has been described herein with reference to various embodiments. However, those skilled in the art will recognize that changes and modifications may be made to any of the various embodiments without departing from the scope of the invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, for example, various of the steps may be deleted, modified, or combined with other steps.


Further, it should be noted that while the methods and systems for ultrasound treatment, as described herein, are suitable for use by a medical practitioner proximate the patient, the system can also be accessed remotely, for example, the medical practitioner can view through a remote display having imaging information transmitted in various manners of communication, such as by satellite/wireless or by wired connections such as IP or digital cable networks and the like, and can direct a local practitioner as to the suitable placement for the transducer. Moreover, while the various embodiments may comprise non-invasive configurations, systems and methods can also be configured for at least some level of invasive treatment applications.


The various embodiments, as disclosed and illustrated herein, are not to be considered in a limiting sense as numerous variations are possible. The subject matter of the various embodiments of the invention includes any and all novel and non-obvious combinations and sub combinations of the various elements, features, functions and/or properties disclosed herein. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

Claims
  • 1. A method of providing non-invasive ultrasound treatment of tissue, the method comprising: coupling an acoustic source to a region of interest comprising a surface and subcutaneous tissue;providing a first acoustic energy into the subcutaneous tissue of the region of interest;
  • 2. The method according to claim 1, further comprising reflecting a portion of the second acoustic energy off of at least one of the thermal bubbles in the boundary and directing a reflected portion of the second acoustic energy into the inner portion of the region of interest.
  • 3. The method according to claim 2, further comprising directing the reflected portion of the second acoustic energy away from the tissue outside of the inner portion.
  • 4. The method according to claim 2, further comprising scattering the reflected portion of the second acoustic energy into the inner portion of the region of interest.
  • 5. The method according to claim 2, further comprising concentrating the second acoustic energy into the inner portion of the region of interest.
  • 6. The method according to claim 1, wherein the second acoustic energy stimulates a bio-effect in the inner portion of the region of interest.
  • 7. The method according to claim 6, wherein the bio-effect in the inner portion of the region of interest is reducing a volume of the subcutaneous tissue.
  • 8. The method according to claim 6, the bio-effect in the inner portion of the region of interest is enhancing formation of collagen in the region of interest.
  • 9. The method according to claim 1, wherein the tissue outside of the region of interest comprises an internal organ.
  • 10. A method of cosmetic enhancement, the method comprising: coupling at least one source to a region of interest;directing a first energy from the at least one source into the region of interest;creating a boundary comprising a plurality of thermal bubbles in a non-target region with the first energy, thereby surrounding a target region in the region of interest with the boundary; anddirecting a second energy from the at least one source inside the boundary and into the target region in the region of interest.
  • 11. The method according to claim 10, further comprising reflecting a portion of the second energy off of at least one of the thermal bubbles in the boundary and directing a reflected portion of the second energy into the target region.
  • 12. The method according to claim 11, further comprising concentrating the second energy into the target region.
  • 13. The method according to claim 10, wherein the second energy stimulates a bio-effect in at least a portion of the target region.
  • 14. The method according to claim 13, wherein the bio-effect in at least a portion of the target region is reducing a volume of tissue in the target region.
  • 15. The method according to claim 13, wherein the bio-effect in at least a portion of the target region is enhancing formation of collagen in the target region.
  • 16. The method according to claim 10, wherein the at least one source comprises an ultrasound source and a pulsed laser.
  • 17. The method according to claim 10, wherein the first energy is ultrasound energy and the second energy is photon-based energy.
  • 18. The method according to claim 10, wherein the first energy is ultrasound energy and the second energy is ultrasound energy.
  • 19. The method according to claim 10, wherein tissue in the non-target region comprises an internal organ.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/954,484 entitled “METHODS AND SYSTEMS FOR GENERATING THERMAL BUBBLES FOR IMPROVED ULTRASOUND IMAGING AND THERAPY” filed on Nov. 24, 2010, issued as U.S. Pat. No. 8,715,186 on May 6, 2014, which claims the benefit of priority from U.S. Provisional No. 61/293,916 filed Nov. 24, 2009, all of which are incorporated in its entirety by reference, herein.

US Referenced Citations (823)
Number Name Date Kind
2427348 Bond et al. Sep 1947 A
3913386 Saglio Oct 1975 A
3965455 Hurwitz Jun 1976 A
3992925 Perilhou Nov 1976 A
4039312 Patru Aug 1977 A
4059098 Murdock Nov 1977 A
4101795 Fukumoto Jul 1978 A
4166967 Benes et al. Sep 1979 A
4211948 Brisken et al. Jul 1980 A
4211949 Brisken et al. Jul 1980 A
4213344 Rose Jul 1980 A
4276491 Daniel Jun 1981 A
4315514 Drewes et al. Feb 1982 A
4325381 Glenn Apr 1982 A
4343301 Indech Aug 1982 A
4372296 Fahim Feb 1983 A
4379145 Masuho et al. Apr 1983 A
4381007 Doss Apr 1983 A
4381787 Hottinger May 1983 A
4397314 Vaguine Aug 1983 A
4409839 Tanezer Oct 1983 A
4431008 Wanner et al. Feb 1984 A
4441486 Pounds Apr 1984 A
4452084 Taenzer Jun 1984 A
4484569 Driller et al. Nov 1984 A
4507582 Glenn Mar 1985 A
4513749 Kino Apr 1985 A
4513750 Heyman et al. Apr 1985 A
4527550 Ruggera et al. Jul 1985 A
4528979 Marchenko Jul 1985 A
4534221 Fife et al. Aug 1985 A
4566459 Umemura et al. Jan 1986 A
4567895 Putzke Feb 1986 A
4586512 Do-Huu May 1986 A
4601296 Yerushalmi Jul 1986 A
4620546 Aida et al. Nov 1986 A
4637256 Sugiyama et al. Jan 1987 A
4646756 Watmough et al. Mar 1987 A
4663358 Hyon May 1987 A
4668516 Duraffourd et al. May 1987 A
4672591 Breimesser et al. Jun 1987 A
4680499 Umemura et al. Jul 1987 A
4697588 Reichenberger Oct 1987 A
4754760 Fukukita et al. Jul 1988 A
4757820 Itoh Jul 1988 A
4771205 Mequio Sep 1988 A
4801459 Liburdy Jan 1989 A
4803625 Fu et al. Feb 1989 A
4807633 Fry Feb 1989 A
4817615 Fukukita et al. Apr 1989 A
4858613 Fry et al. Aug 1989 A
4860732 Hasegawa et al. Aug 1989 A
4865041 Hassler Sep 1989 A
4865042 Umemura Sep 1989 A
4867169 Machida Sep 1989 A
4874562 Hyon Oct 1989 A
4875487 Seppi Oct 1989 A
4891043 Zeimer et al. Jan 1990 A
4893624 Lele Jan 1990 A
4896673 Rose Jan 1990 A
4900540 Ryan et al. Feb 1990 A
4901729 Saitoh et al. Feb 1990 A
4917096 Englehart Apr 1990 A
4932414 Coleman et al. Jun 1990 A
4938216 Lele Jul 1990 A
4938217 Lele Jul 1990 A
4947046 Kawabata et al. Aug 1990 A
4951653 Fry et al. Aug 1990 A
4955365 Fry et al. Sep 1990 A
4958626 Nambu Sep 1990 A
4976709 Sand Dec 1990 A
4979501 Valchanov Dec 1990 A
4992989 Watanabe et al. Feb 1991 A
5012797 Liang May 1991 A
5018508 Fry et al. May 1991 A
5030874 Saito et al. Jul 1991 A
5036855 Fry et al. Aug 1991 A
5040537 Katakura Aug 1991 A
5054310 Flynn Oct 1991 A
5054470 Fry et al. Oct 1991 A
5070879 Herres Dec 1991 A
5088495 Miyagawa Feb 1992 A
5115814 Griffith May 1992 A
5117832 Sanghvi et al. Jun 1992 A
5123418 Saurel Jun 1992 A
5143063 Fellner Sep 1992 A
5143074 Dory Sep 1992 A
5149319 Unger Sep 1992 A
5150711 Dory Sep 1992 A
5150714 Green Sep 1992 A
5152294 Mochizuki et al. Oct 1992 A
5156144 Iwasaki Oct 1992 A
5158536 Sekins Oct 1992 A
5159931 Pini Nov 1992 A
5163421 Bernstein Nov 1992 A
5163436 Saitoh et al. Nov 1992 A
5178135 Uchiyama et al. Jan 1993 A
5190518 Takasu Mar 1993 A
5190766 Ishihara Mar 1993 A
5191880 McLeod Mar 1993 A
5205287 Erbel et al. Apr 1993 A
5209720 Unger May 1993 A
5212671 Fujii et al. May 1993 A
5215680 D Arrigo Jun 1993 A
5224467 Oku Jul 1993 A
5230334 Klopotek Jul 1993 A
5230338 Allen et al. Jul 1993 A
5247924 Suzuki et al. Sep 1993 A
5255681 Ishimura et al. Oct 1993 A
5257970 Dougherty Nov 1993 A
5265614 Hayakawa Nov 1993 A
5267985 Shimada et al. Dec 1993 A
5269297 Weng Dec 1993 A
5282797 Chess Feb 1994 A
5295484 Marcus et al. Mar 1994 A
5295486 Wollschlaeger et al. Mar 1994 A
5304169 Sand Apr 1994 A
5305756 Entrekin et al. Apr 1994 A
5321520 Inga et al. Jun 1994 A
5323779 Hardy et al. Jun 1994 A
5327895 Hashimoto et al. Jul 1994 A
5348016 Unger et al. Sep 1994 A
5360268 Hayashi Nov 1994 A
5370121 Reichenberger et al. Dec 1994 A
5371483 Bhardwaj Dec 1994 A
5375602 Lancee et al. Dec 1994 A
5379773 Hornsby Jan 1995 A
5380280 Peterson Jan 1995 A
5380519 Schneider et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5391140 Schaetzle et al. Feb 1995 A
5391197 Burdette et al. Feb 1995 A
5392259 Bolorforosh Feb 1995 A
5396143 Seyed-Bolorforosh et al. Mar 1995 A
5398689 Connor et al. Mar 1995 A
5406503 Williams, Jr. et al. Apr 1995 A
5417216 Tanaka May 1995 A
5419327 Rohwedder May 1995 A
5423220 Finsterwald et al. Jun 1995 A
5435311 Umemura et al. Jul 1995 A
5438998 Hanafy Aug 1995 A
5458596 Lax Oct 1995 A
5460179 Okunuki et al. Oct 1995 A
5460595 Hall et al. Oct 1995 A
5469854 Unger et al. Nov 1995 A
5471988 Fujio Dec 1995 A
5487388 Rello et al. Jan 1996 A
5492126 Hennige et al. Feb 1996 A
5496256 Bock Mar 1996 A
5501655 Rolt et al. Mar 1996 A
5503152 Oakley et al. Apr 1996 A
5503320 Webster et al. Apr 1996 A
5507790 Weiss Apr 1996 A
5520188 Hennige et al. May 1996 A
5522869 Burdette et al. Jun 1996 A
5523058 Umemura et al. Jun 1996 A
5524620 Rosenschein Jun 1996 A
5524624 Tepper Jun 1996 A
5524625 Okazaki et al. Jun 1996 A
5526624 Berg Jun 1996 A
5526812 Dumoulin et al. Jun 1996 A
5526814 Cline et al. Jun 1996 A
5526815 Granz et al. Jun 1996 A
5529070 Augustine et al. Jun 1996 A
5540235 Wilson Jul 1996 A
5558092 Unger et al. Sep 1996 A
5560362 Sliwa et al. Oct 1996 A
5575291 Hayakawa Nov 1996 A
5575807 Faller Nov 1996 A
5577502 Darrow et al. Nov 1996 A
5577507 Snyder et al. Nov 1996 A
5577991 Akui et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5601526 Chapelon et al. Feb 1997 A
5603323 Pflugrath et al. Feb 1997 A
5609562 Kaali Mar 1997 A
5615091 Palatnik Mar 1997 A
5617858 Taverna et al. Apr 1997 A
5618275 Bock Apr 1997 A
5620479 Diederich Apr 1997 A
5622175 Sudol et al. Apr 1997 A
5638819 Manwaring et al. Jun 1997 A
5643179 Fujimoto Jul 1997 A
5644085 Lorraine et al. Jul 1997 A
5647373 Paltieli Jul 1997 A
5655535 Friemel et al. Aug 1997 A
5655538 Lorraine Aug 1997 A
5657760 Ying et al. Aug 1997 A
5658328 Johnson Aug 1997 A
5660836 Knowlton Aug 1997 A
5662116 Kondo et al. Sep 1997 A
5665053 Jacobs Sep 1997 A
5665141 Vago Sep 1997 A
5671746 Dreschel et al. Sep 1997 A
5673699 Trahey et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5685820 Riek et al. Nov 1997 A
5687737 Branham et al. Nov 1997 A
5690608 Watanabe Nov 1997 A
5694936 Fujimoto et al. Dec 1997 A
5697897 Buchholtz et al. Dec 1997 A
5701900 Shehada et al. Dec 1997 A
5704361 Seward et al. Jan 1998 A
5706252 Le Verrier et al. Jan 1998 A
5706564 Rhyne Jan 1998 A
5715823 Wood et al. Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722411 Suzuki et al. Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5743863 Chapelon Apr 1998 A
5746005 Steinberg May 1998 A
5746762 Bass May 1998 A
5748767 Raab May 1998 A
5749364 Sliwa et al. May 1998 A
5755228 Wilson et al. May 1998 A
5755753 Knowlton May 1998 A
5762066 Law et al. Jun 1998 A
5763886 Schulte Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5779644 Eberle et al. Jul 1998 A
5792058 Lee et al. Aug 1998 A
5795297 Daigle Aug 1998 A
5795311 Wess Aug 1998 A
5810009 Mine et al. Sep 1998 A
5810888 Fenn Sep 1998 A
5814599 Mitragotri et al. Sep 1998 A
5817013 Ginn et al. Oct 1998 A
5817021 Reichenberger Oct 1998 A
5820564 Slayton Oct 1998 A
5823962 Schaetzle et al. Oct 1998 A
5827204 Grandia et al. Oct 1998 A
5839751 Bonin Nov 1998 A
5840032 Hatfield et al. Nov 1998 A
5844140 Seale Dec 1998 A
5853367 Chalek et al. Dec 1998 A
5869751 Bonin Feb 1999 A
5871524 Knowlton Feb 1999 A
5873902 Sanghvi et al. Feb 1999 A
5876431 Spehr et al. Mar 1999 A
5879303 Averkiou et al. Mar 1999 A
5882557 Hayakawa Mar 1999 A
5891034 Bucholz Apr 1999 A
5899861 Friemel et al. May 1999 A
5904659 Duarte May 1999 A
5919219 Knowlton Jul 1999 A
5923099 Bilir Jul 1999 A
5924989 Polz Jul 1999 A
5928169 Schaetzle et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5938606 Bonnefous Aug 1999 A
5938612 Kline-Schoder Aug 1999 A
5948011 Knowlton Sep 1999 A
5957844 Dekel Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream Sep 1999 A
5967980 Ferre et al. Oct 1999 A
5968034 Fulmer Oct 1999 A
5971949 Levin Oct 1999 A
5977538 Unger et al. Nov 1999 A
5984882 Rosenschein et al. Nov 1999 A
5990598 Sudol et al. Nov 1999 A
5997471 Gumb et al. Dec 1999 A
5997497 Nita et al. Dec 1999 A
5999843 Anbar Dec 1999 A
6004262 Putz et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6013032 Savord Jan 2000 A
6016255 Bolan et al. Jan 2000 A
6019724 Gronningsaeter et al. Feb 2000 A
6022308 Williams Feb 2000 A
6022327 Chang Feb 2000 A
6036646 Barthe Mar 2000 A
6039048 Silberg Mar 2000 A
6039689 Lizzi Mar 2000 A
6042556 Beach et al. Mar 2000 A
6049159 Barthe Apr 2000 A
6050943 Slayton et al. Apr 2000 A
6059727 Fowlkes May 2000 A
6071239 Cribbs et al. Jun 2000 A
6080108 Dunham Jun 2000 A
6083148 Williams Jul 2000 A
6086535 Ishibashi et al. Jul 2000 A
6086580 Mordon et al. Jul 2000 A
6090054 Tagishi Jul 2000 A
6093883 Sanghvi Jul 2000 A
6101407 Groezinger Aug 2000 A
6106469 Suzuki et al. Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113559 Klopotek Sep 2000 A
6120452 Barthe Sep 2000 A
6123081 Durette Sep 2000 A
6126619 Peterson et al. Oct 2000 A
6135971 Hutchinson et al. Oct 2000 A
6139499 Wilk Oct 2000 A
6159150 Yale et al. Dec 2000 A
6171244 Finger et al. Jan 2001 B1
6176840 Nishimura Jan 2001 B1
6183426 Akisada Feb 2001 B1
6183502 Takeuchi Feb 2001 B1
6183773 Anderson Feb 2001 B1
6190323 Digs Feb 2001 B1
6190336 Duarte Feb 2001 B1
6193658 Wendelken et al. Feb 2001 B1
6210327 Brackett et al. Apr 2001 B1
6213948 Barthe Apr 2001 B1
6216029 Paltieli Apr 2001 B1
6233476 Strommer et al. May 2001 B1
6234990 Rowe et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6246898 Vesely et al. Jun 2001 B1
6251074 Averkiou et al. Jun 2001 B1
6251088 Kaufman et al. Jun 2001 B1
6268405 Yao Jul 2001 B1
6273864 Duarte Aug 2001 B1
6280402 Ishibashi et al. Aug 2001 B1
6287257 Matichuk Sep 2001 B1
6296619 Brisken Oct 2001 B1
6301989 Brown et al. Oct 2001 B1
6309355 Cain et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6315741 Martin Nov 2001 B1
6322509 Pan et al. Nov 2001 B1
6322532 D'Sa Nov 2001 B1
6325540 Lounsberry et al. Dec 2001 B1
6325758 Carol et al. Dec 2001 B1
6325769 Klopotek Dec 2001 B1
6325798 Edwards et al. Dec 2001 B1
6338716 Hossack et al. Jan 2002 B1
6350276 Knowlton Feb 2002 B1
6356780 Licato et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6370411 Osadchy et al. Apr 2002 B1
6375672 Aksan Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6390982 Bova et al. May 2002 B1
6405090 Knowlton Jun 2002 B1
6409720 Hissong Jun 2002 B1
6413216 Cain et al. Jul 2002 B1
6413253 Koop Jul 2002 B1
6413254 Hissong Jul 2002 B1
6419648 Vitek Jul 2002 B1
6423007 Lizzi et al. Jul 2002 B2
6425865 Salcudean Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6428477 Mason Aug 2002 B1
6428532 Doukas Aug 2002 B1
6430446 Knowlton Aug 2002 B1
6432057 Mazess et al. Aug 2002 B1
6432067 Martin et al. Aug 2002 B1
6432101 Weber Aug 2002 B1
6436061 Costantino Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440071 Slayton Aug 2002 B1
6440121 Weber Aug 2002 B1
6443914 Costantino Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6488626 Lizzi et al. Dec 2002 B1
6491657 Rowe Dec 2002 B2
6500121 Slayton Dec 2002 B1
6500141 Irion Dec 2002 B1
6508774 Acker et al. Jan 2003 B1
6511427 Sliwa, Jr. et al. Jan 2003 B1
6511428 Azuma Jan 2003 B1
6514244 Pope Feb 2003 B2
6517484 Wilk et al. Feb 2003 B1
6524250 Weber Feb 2003 B1
6540679 Slayton Apr 2003 B2
6540685 Rhoads et al. Apr 2003 B1
6540700 Fujimoto et al. Apr 2003 B1
6554771 Buil et al. Apr 2003 B1
6569099 Babaev May 2003 B1
6569108 Sarvazyan et al. May 2003 B2
6572552 Fukukita Jun 2003 B2
6575956 Brisken et al. Jun 2003 B1
6595934 Hissong Jul 2003 B1
6599256 Acker Jul 2003 B1
6607498 Eshel Aug 2003 B2
6618620 Freundlich et al. Sep 2003 B1
6623430 Slayton Sep 2003 B1
6626854 Friedman Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6638226 He et al. Oct 2003 B2
6645162 Friedman Nov 2003 B2
6662054 Kreindel Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6665806 Shimizu Dec 2003 B1
6666835 Martin Dec 2003 B2
6669638 Miller et al. Dec 2003 B1
6685640 Fry Feb 2004 B1
6692450 Coleman Feb 2004 B1
6699237 Weber Mar 2004 B2
6716184 Vaezy et al. Apr 2004 B2
6719449 Lauglin Apr 2004 B1
6719694 Weng et al. Apr 2004 B2
6726627 Lizzi et al. Apr 2004 B1
6825176 Mourad Apr 2004 B2
6733449 Krishnamurthy et al. May 2004 B1
6749624 Knowlton Jun 2004 B2
6773409 Truckai et al. Aug 2004 B2
6775404 Pagoulatos et al. Aug 2004 B1
6790187 Thompson et al. Sep 2004 B2
6824516 Batten et al. Nov 2004 B2
6835940 Morikawa et al. Dec 2004 B2
6846290 Lizzi et al. Jan 2005 B2
6875176 Mourad et al. Apr 2005 B2
6882884 Mosk et al. Apr 2005 B1
6887239 Elstrom et al. May 2005 B2
6889089 Behl May 2005 B2
6896657 Willis May 2005 B2
6902536 Manna et al. Jun 2005 B2
6905466 Salgo Jun 2005 B2
6918907 Kelly Jul 2005 B2
6920883 Bessette Jul 2005 B2
6921371 Wilson Jul 2005 B2
6932771 Whitmore Aug 2005 B2
6932814 Wood Aug 2005 B2
6936044 McDaniel Aug 2005 B2
6936046 Hissong Aug 2005 B2
6945937 Culp et al. Sep 2005 B2
6948843 Laugharn et al. Sep 2005 B2
6953941 Nakano et al. Oct 2005 B2
6958043 Hissong Oct 2005 B2
6971994 Young et al. Dec 2005 B1
6974417 Lockwood et al. Dec 2005 B2
6976492 Ingle Dec 2005 B2
6992305 Maezawa et al. Jan 2006 B2
6997923 Anderson Feb 2006 B2
7006874 Knowlton Feb 2006 B2
7020528 Neev Mar 2006 B2
7022089 Ooba Apr 2006 B2
7058440 Heuscher et al. Jun 2006 B2
7063666 Weng et al. Jun 2006 B2
7070565 Vaezy et al. Jul 2006 B2
7074218 Washington et al. Jul 2006 B2
7094252 Koop Aug 2006 B2
7108663 Talish et al. Sep 2006 B2
7115123 Knowlton Oct 2006 B2
7122029 Koop et al. Oct 2006 B2
7142905 Slayton Nov 2006 B2
7165451 Brooks et al. Jan 2007 B1
7179238 Hissong Feb 2007 B2
7189230 Knowlton Mar 2007 B2
7229411 Slayton Jun 2007 B2
7235592 Muratoglu Jun 2007 B2
7258674 Cribbs Aug 2007 B2
7273459 Desilets Sep 2007 B2
7294125 Phalen et al. Nov 2007 B2
7297117 Trucco et al. Nov 2007 B2
7303555 Makin et al. Dec 2007 B2
7327071 Nishiyama et al. Feb 2008 B2
7331951 Eshel et al. Feb 2008 B2
7332985 Larson, III et al. Feb 2008 B2
7347855 Eshel Mar 2008 B2
RE40403 Cho et al. Jun 2008 E
7393325 Barthe Jul 2008 B2
7398116 Edwards Jul 2008 B2
7399279 Abend et al. Jul 2008 B2
7491171 Barthe et al. Feb 2009 B2
7510536 Foley et al. Mar 2009 B2
7530356 Slayton May 2009 B2
7530958 Slayton May 2009 B2
7571336 Barthe Aug 2009 B2
7601120 Moilanen et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615016 Barthe Nov 2009 B2
7686763 Vaezy et al. Mar 2010 B2
7695437 Quistgaard et al. Apr 2010 B2
7758524 Barthe Jul 2010 B2
7789841 Huckle et al. Sep 2010 B2
7824348 Barthe et al. Nov 2010 B2
7846096 Mast et al. Dec 2010 B2
7857773 Desilets et al. Dec 2010 B2
7875023 Eshel et al. Jan 2011 B2
7914453 Slayton et al. Mar 2011 B2
7914469 Torbati Mar 2011 B2
7931611 Novak et al. Apr 2011 B2
7955281 Pedersen et al. Jun 2011 B2
7967764 Lidgren et al. Jun 2011 B2
7967839 Flock et al. Jun 2011 B2
8057389 Barthe et al. Nov 2011 B2
8057465 Sliwa, Jr. et al. Nov 2011 B2
8066641 Barthe et al. Nov 2011 B2
8123707 Huckle et al. Feb 2012 B2
8128618 Gliklich et al. Mar 2012 B2
8133180 Slayton et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8166332 Barthe et al. Apr 2012 B2
8197409 Foley et al. Jun 2012 B2
8206299 Foley et al. Jun 2012 B2
8211017 Foley et al. Jul 2012 B2
8262591 Pedersen et al. Sep 2012 B2
8273037 Kreindel et al. Sep 2012 B2
8282554 Makin et al. Oct 2012 B2
8333700 Barthe et al. Dec 2012 B1
8366622 Slayton et al. Feb 2013 B2
8409097 Slayton et al. Apr 2013 B2
8444562 Barthe et al. May 2013 B2
8480585 Slayton et al. Jul 2013 B2
8506486 Slayton et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8585618 Hunziker et al. Nov 2013 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8708935 Barthe et al. Apr 2014 B2
8715186 Slayton et al. May 2014 B2
8726781 Eckhoff et al. May 2014 B2
20010009997 Pope Jul 2001 A1
20010009999 Kaufman et al. Jul 2001 A1
20010014780 Martin et al. Aug 2001 A1
20010014819 Ingle et al. Aug 2001 A1
20010031922 Weng et al. Oct 2001 A1
20010039380 Larson et al. Nov 2001 A1
20010041880 Brisken Nov 2001 A1
20020000763 Jones Jan 2002 A1
20020002345 Marlinghaus Jan 2002 A1
20020040199 Klopotek Apr 2002 A1
20020040442 Ishidera Apr 2002 A1
20020052550 Madsen et al. May 2002 A1
20020055702 Atala May 2002 A1
20020062077 Emmenegger et al. May 2002 A1
20020062142 Knowlton May 2002 A1
20020072691 Thompson et al. Jun 2002 A1
20020082528 Friedman et al. Jun 2002 A1
20020082529 Suorsa et al. Jun 2002 A1
20020082589 Friedman et al. Jun 2002 A1
20020087080 Slayton et al. Jul 2002 A1
20020095143 Key Jul 2002 A1
20020099094 Anderson Jul 2002 A1
20020115917 Honda et al. Aug 2002 A1
20020128648 Weber Sep 2002 A1
20020143252 Dunne et al. Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20020161357 Anderson Oct 2002 A1
20020165529 Danek Nov 2002 A1
20020168049 Schriever Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169442 Neev Nov 2002 A1
20020173721 Grunwald et al. Nov 2002 A1
20020193784 Mchale et al. Dec 2002 A1
20020193831 Smith Dec 2002 A1
20030009153 Brisken et al. Jan 2003 A1
20030014039 Barzell et al. Jan 2003 A1
20030018255 Martin Jan 2003 A1
20030028111 Vaezy et al. Feb 2003 A1
20030028113 Gilbert et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030036706 Slayton et al. Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030050678 Sierra Mar 2003 A1
20030055417 Truckai et al. Mar 2003 A1
20030060736 Martin et al. Mar 2003 A1
20030065313 Koop Apr 2003 A1
20030074023 Kaplan Apr 2003 A1
20030083536 Eshel May 2003 A1
20030092988 Makin May 2003 A1
20030097071 Halmann et al. May 2003 A1
20030099383 Lefevbre May 2003 A1
20030125629 Ustuner Jul 2003 A1
20030139790 Ingle et al. Jul 2003 A1
20030171678 Batten et al. Sep 2003 A1
20030171701 Babaev Sep 2003 A1
20030176790 Slayton Sep 2003 A1
20030191396 Sanghvi Oct 2003 A1
20030200481 Stanley Oct 2003 A1
20030212129 Liu et al. Nov 2003 A1
20030212351 Hissong Nov 2003 A1
20030212393 Knowlton Nov 2003 A1
20030216795 Harth Nov 2003 A1
20030220536 Hissong Nov 2003 A1
20030220585 Hissong Nov 2003 A1
20030229331 Brisken et al. Dec 2003 A1
20030233085 Giammarusti Dec 2003 A1
20030236487 Knowlton Dec 2003 A1
20040000316 Knowlton Jan 2004 A1
20040001809 Brisken Jan 2004 A1
20040002705 Knowlton Jan 2004 A1
20040010222 Nunomura et al. Jan 2004 A1
20040015106 Coleman Jan 2004 A1
20040030227 Littrup Feb 2004 A1
20040039312 Hillstead Feb 2004 A1
20040039418 Elstrom et al. Feb 2004 A1
20040041563 Lewin et al. Mar 2004 A1
20040041880 Ikeda et al. Mar 2004 A1
20040042168 Yang et al. Mar 2004 A1
20040044375 Diederich et al. Mar 2004 A1
20040049134 Tosaya et al. Mar 2004 A1
20040049734 Simske Mar 2004 A1
20040059266 Fry Mar 2004 A1
20040068186 Ishida et al. Apr 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040073113 Salgo Apr 2004 A1
20040073115 Horzewski et al. Apr 2004 A1
20040073116 Smith Apr 2004 A1
20040073204 Ryan et al. Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082857 Schonenberger et al. Apr 2004 A1
20040082859 Schaer Apr 2004 A1
20040102697 Evron May 2004 A1
20040105559 Aylward et al. Jun 2004 A1
20040122323 Vortman et al. Jun 2004 A1
20040122493 Ishbashi et al. Jun 2004 A1
20040143297 Ramsey Jul 2004 A1
20040152982 Hwang et al. Aug 2004 A1
20040158150 Rabiner et al. Aug 2004 A1
20040186535 Knowlton Sep 2004 A1
20040189155 Funakubo Sep 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040217675 Desilets Nov 2004 A1
20040249318 Tanaka Dec 2004 A1
20040254620 Lacoste et al. Dec 2004 A1
20040267252 Washington et al. Dec 2004 A1
20050033201 Takahashi Feb 2005 A1
20050033316 Kertz Feb 2005 A1
20050038340 Vaezy et al. Feb 2005 A1
20050055073 Weber Mar 2005 A1
20050061834 Garcia et al. Mar 2005 A1
20050070961 Maki et al. Mar 2005 A1
20050074407 Smith Apr 2005 A1
20050080469 Larson Apr 2005 A1
20050091770 Mourad et al. May 2005 A1
20050096542 Weng et al. May 2005 A1
20050104690 Larson, III et al. May 2005 A1
20050113689 Gritzky May 2005 A1
20050134314 Prather et al. Jun 2005 A1
20050137656 Malak Jun 2005 A1
20050143677 Young et al. Jun 2005 A1
20050154313 Desilets Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154332 Zanelli Jul 2005 A1
20050154431 Quistgaard Jul 2005 A1
20050187495 Quistgaard Aug 2005 A1
20050191252 Mitsui Sep 2005 A1
20050193451 Quistgaard et al. Sep 2005 A1
20050197681 Barolet et al. Sep 2005 A1
20050228281 Nefos Oct 2005 A1
20050240170 Zhang et al. Oct 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050256406 Barthe Nov 2005 A1
20050261584 Eshel Nov 2005 A1
20050261585 Makin et al. Nov 2005 A1
20050267454 Hissong Dec 2005 A1
20050288748 Li et al. Dec 2005 A1
20060004306 Altshuler Jan 2006 A1
20060020260 Dover et al. Jan 2006 A1
20060025756 Francischelli Feb 2006 A1
20060042201 Curry Mar 2006 A1
20060058664 Barthe Mar 2006 A1
20060058671 Vitek et al. Mar 2006 A1
20060058707 Barthe Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060074309 Bonnefous Apr 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060074314 Slayton Apr 2006 A1
20060074355 Slayton Apr 2006 A1
20060079816 Barthe Apr 2006 A1
20060079868 Makin Apr 2006 A1
20060084891 Barthe Apr 2006 A1
20060089632 Barthe Apr 2006 A1
20060089688 Panescu Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060111744 Makin May 2006 A1
20060116583 Ogasawara et al. Jun 2006 A1
20060116671 Slayton Jun 2006 A1
20060122508 Slayton Jun 2006 A1
20060122509 Desilets Jun 2006 A1
20060161062 Arditi et al. Jul 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060184071 Klopotek Aug 2006 A1
20060189972 Grossman Aug 2006 A1
20060206105 Chopra Sep 2006 A1
20060229514 Wiener Oct 2006 A1
20060241440 Eshel Oct 2006 A1
20060241442 Barthe Oct 2006 A1
20060241470 Novak et al. Oct 2006 A1
20060250046 Koizumi et al. Nov 2006 A1
20060261584 Eshel Nov 2006 A1
20060282691 Barthe Dec 2006 A1
20060291710 Wang et al. Dec 2006 A1
20070032784 Gliklich et al. Feb 2007 A1
20070035201 Desilets Feb 2007 A1
20070055154 Torbati Mar 2007 A1
20070055155 Owen et al. Mar 2007 A1
20070055156 Desilets Mar 2007 A1
20070065420 Johnson Mar 2007 A1
20070083120 Cain et al. Apr 2007 A1
20070087060 Dietrich Apr 2007 A1
20070088245 Babaev et al. Apr 2007 A1
20070088346 Mirizzi et al. Apr 2007 A1
20070161902 Dan Jul 2007 A1
20070166357 Shaffer et al. Jul 2007 A1
20070167709 Slayton Jul 2007 A1
20070208253 Slayton Sep 2007 A1
20070219604 Yaroslavsky et al. Sep 2007 A1
20070219605 Yaroslavsky et al. Sep 2007 A1
20070238994 Stecco et al. Oct 2007 A1
20070239075 Rosenberg et al. Oct 2007 A1
20070239079 Manstein et al. Oct 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20080027328 Klopotek et al. Jan 2008 A1
20080039724 Seip et al. Feb 2008 A1
20080071255 Barthe Mar 2008 A1
20080086054 Slayton Apr 2008 A1
20080097253 Pedersen Apr 2008 A1
20080139974 Da Silva Jun 2008 A1
20080146970 Litman et al. Jun 2008 A1
20080167556 Thompson et al. Jul 2008 A1
20080183077 Moreau-Gobard et al. Jul 2008 A1
20080188745 Chen et al. Aug 2008 A1
20080195000 Spooner et al. Aug 2008 A1
20080200810 Buchalter Aug 2008 A1
20080200813 Quistgaard Aug 2008 A1
20080214966 Slayton Sep 2008 A1
20080221491 Slayton Sep 2008 A1
20080223379 Stuker et al. Sep 2008 A1
20080243035 Crunkilton Oct 2008 A1
20080269608 Anderson et al. Oct 2008 A1
20080275342 Barthe Nov 2008 A1
20080281206 Bartlett et al. Nov 2008 A1
20080281236 Eshel et al. Nov 2008 A1
20080281237 Slayton Nov 2008 A1
20080281255 Slayton Nov 2008 A1
20080294073 Barthe et al. Nov 2008 A1
20080319356 Cain et al. Dec 2008 A1
20090005680 Jones et al. Jan 2009 A1
20090012394 Hobelsberger et al. Jan 2009 A1
20090043198 Milner et al. Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090069677 Chen et al. Mar 2009 A1
20090093737 Chomas et al. Apr 2009 A1
20090156969 Santangelo Jun 2009 A1
20090171252 Bockenstedt et al. Jul 2009 A1
20090177122 Peterson Jul 2009 A1
20090177123 Peterson Jul 2009 A1
20090182231 Barthe et al. Jul 2009 A1
20090216159 Slayton et al. Aug 2009 A1
20090226424 Hsu Sep 2009 A1
20090227910 Pedersen et al. Sep 2009 A1
20090253988 Slayton et al. Oct 2009 A1
20090299175 Bernstein et al. Dec 2009 A1
20090318909 Debenedictis et al. Dec 2009 A1
20100011236 Barthe et al. Jan 2010 A1
20100022919 Peterson Jan 2010 A1
20100022922 Barthe et al. Jan 2010 A1
20100042020 Ben-Ezra Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100063422 Hynynen et al. Mar 2010 A1
20100130891 Taggart et al. May 2010 A1
20100160782 Slayton et al. Jun 2010 A1
20100160837 Hunziker et al. Jun 2010 A1
20100168576 Poland et al. Jul 2010 A1
20100191120 Kraus et al. Jul 2010 A1
20100241035 Barthe et al. Sep 2010 A1
20100280420 Barthe et al. Nov 2010 A1
20100286518 Lee et al. Nov 2010 A1
20110040171 Foley et al. Feb 2011 A1
20110040190 Jahnke et al. Feb 2011 A1
20110087099 Eshel et al. Apr 2011 A1
20110087255 Mccormack et al. Apr 2011 A1
20110112405 Barthe et al. May 2011 A1
20110178444 Slayton et al. Jul 2011 A1
20110190745 Uebelhoer et al. Aug 2011 A1
20110264012 Lautzenhiser et al. Oct 2011 A1
20120004549 Barthe et al. Jan 2012 A1
20120016239 Barthe et al. Jan 2012 A1
20120029353 Slayton et al. Feb 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120111339 Barthe et al. May 2012 A1
20120143056 Slayton et al. Jun 2012 A1
20120165668 Slayton et al. Jun 2012 A1
20120165848 Slayton et al. Jun 2012 A1
20120197120 Makin et al. Aug 2012 A1
20120197121 Slayton et al. Aug 2012 A1
20120215105 Slayton et al. Aug 2012 A1
20120271294 Barthe et al. Oct 2012 A1
20120296240 Azhari et al. Nov 2012 A1
20120316426 Foley et al. Dec 2012 A1
20120330197 Makin et al. Dec 2012 A1
20120330222 Barthe et al. Dec 2012 A1
20120330223 Makin et al. Dec 2012 A1
20130012755 Slayton Jan 2013 A1
20130012816 Slayton et al. Jan 2013 A1
20130012838 Jaeger et al. Jan 2013 A1
20130012842 Barthe Jan 2013 A1
20130018286 Slayton et al. Jan 2013 A1
20130046209 Slayton et al. Feb 2013 A1
20130066208 Barthe et al. Mar 2013 A1
20130066237 Smotrich et al. Mar 2013 A1
20130072826 Slayton et al. Mar 2013 A1
20130096471 Slayton et al. Apr 2013 A1
20130190659 Slayton et al. Jul 2013 A1
20130211258 Barthe et al. Aug 2013 A1
20130281853 Slayton et al. Oct 2013 A1
20130281891 Slayton et al. Oct 2013 A1
20130296697 Slayton et al. Nov 2013 A1
20130296700 Slayton et al. Nov 2013 A1
20130303904 Barthe et al. Nov 2013 A1
20130303905 Barthe et al. Nov 2013 A1
20130310863 Barthe et al. Nov 2013 A1
20140082907 Barthe Mar 2014 A1
20140142430 Slayton et al. May 2014 A1
20140148834 Barthe et al. May 2014 A1
20140180174 Slayton et al. Jun 2014 A1
20140187944 Slayton et al. Jul 2014 A1
20140188015 Slayton et al. Jul 2014 A1
20140188145 Slayton et al. Jul 2014 A1
Foreign Referenced Citations (94)
Number Date Country
4029175 Mar 1992 DE
10140064 Mar 2003 DE
10219217 Nov 2003 DE
10219297 Nov 2003 DE
20314479 Mar 2004 DE
0344773 Dec 1989 EP
1479412 Nov 1991 EP
0473553 Mar 1992 EP
0661029 Jul 1995 EP
1050322 Nov 2000 EP
1234566 Aug 2002 EP
1262160 Dec 2002 EP
1374944 Jan 2004 EP
2113099 Aug 1983 GB
63036171 Feb 1988 JP
03048299 Mar 1991 JP
3123559 May 1991 JP
03136642 Jun 1991 JP
4089058 Mar 1992 JP
04150847 May 1992 JP
7080087 Mar 1995 JP
07505793 Jun 1995 JP
7222782 Aug 1995 JP
09047458 Feb 1997 JP
11505440 May 1999 JP
11506636 Jun 1999 JP
2000166940 Jun 2000 JP
2001170068 Jun 2001 JP
2002078764 Mar 2002 JP
2002515786 May 2002 JP
2002521118 Jul 2002 JP
2002537939 Nov 2002 JP
2003050298 Feb 2003 JP
2003204982 Jul 2003 JP
2004147719 May 2004 JP
2005503388 Feb 2005 JP
2005527336 Sep 2005 JP
2005323213 Nov 2005 JP
2006520247 Sep 2006 JP
2007505793 Mar 2007 JP
2009518126 May 2009 JP
2010517695 May 2010 JP
1020010024871 Mar 2001 KR
100400870 Oct 2003 KR
1020060113930 Nov 2006 KR
1020070065332 Jun 2007 KR
1020070070161 Jul 2007 KR
1020070098856 Oct 2007 KR
1020070104878 Oct 2007 KR
1020070114105 Nov 2007 KR
9625888 Aug 1996 WO
9639079 Dec 1996 WO
9735518 Oct 1997 WO
9832379 Jul 1998 WO
9933520 Jul 1999 WO
9949788 Oct 1999 WO
0006032 Feb 2000 WO
0015300 Mar 2000 WO
0021612 Apr 2000 WO
0053113 Sep 2000 WO
0128623 Apr 2001 WO
0182777 Nov 2001 WO
0182778 Nov 2001 WO
0187161 Nov 2001 WO
0209813 Feb 2002 WO
0224050 Mar 2002 WO
02092168 Nov 2002 WO
020292168 Nov 2002 WO
03053266 Jul 2003 WO
03065347 Aug 2003 WO
03070105 Aug 2003 WO
03077833 Aug 2003 WO
03086215 Oct 2003 WO
03096883 Nov 2003 WO
03099177 Dec 2003 WO
03101530 Dec 2003 WO
2004000116 Dec 2003 WO
2004080147 Sep 2004 WO
2004110558 Dec 2004 WO
2005011804 Feb 2005 WO
2005065408 Jul 2005 WO
2005090978 Sep 2005 WO
2006036870 Apr 2006 WO
2006042163 Apr 2006 WO
2006042168 Apr 2006 WO
2006042201 Apr 2006 WO
2006065671 Jun 2006 WO
2006082573 Aug 2006 WO
2007067563 Jun 2007 WO
2008024923 Feb 2008 WO
2008036622 Mar 2008 WO
2009013729 Jan 2009 WO
2009149390 Dec 2009 WO
2014055708 Apr 2014 WO
Non-Patent Literature Citations (70)
Entry
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages.
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fiels,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839.
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med & Biol. vol. 19, No. 2, pp. 123-125 (1993).
Smith, Nadine Barrie, et al., “Non-Invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49.
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555.
Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652.
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
Wasson, Scott, “NVIDIA's GeFroce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages.
White et al “Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1.
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600.
Barthe et al., “Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.
Calderhead et al, One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell, Laser Therapy, Jul. 2008, pp. 141-148, 17.3.
Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound,” Phys. Med. Biol; 38:1661-1673; 1993b.
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 5, 2005, pp. 9463-9468.
European Examination Report in related Application No. 05808908.7 dated Jun. 29, 2009.
European Examination Report in related Application No. 05810308.6 dated Jun. 29, 2009.
European Examination Report in related Application No. 09835856.7 dated Apr. 11, 2004.
European Examination Report in related Application No. 10185100.4 dated Jan. 6, 2014.
European Examination Report in related Application No. 10185120.2 dated Jan. 22, 2014.
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444,456.
Damianou et al., Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery, 1993 IEEE Ultrasound Symposium, pp. 1199-1202.
Daum et al., “Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery,” IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438.
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924.
Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on the pp. 2-5 of the information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954.
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9.
Harr, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993.
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153.
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2).
Husseini et al. “Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046122.
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046123.
International Search Report and Written Opinion dated Jan. 28, 2012 in Application No. PCT/US2012/046327.
International Search Report and Written Opinion dated Jan. 28, 2013 in Application No. PCT/US2012/046125.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001361.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001362.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001366.
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001366.
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001367.
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928.
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882.
Johnson, S.A., et al., “Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982.
Madersbacher, S. et al., “Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993.
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
Makin et al, “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
Makin et al., “Confirmal Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays”, 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.
Manohar et al, “Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
Mitragotri, Samir; “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4.
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14.
PCT/US2012/046122 International Search Report Jan. 30, 2013.
PCT/US2012/046123 International Search Report Jan. 28, 2013.
PCT/US2012/046125 International Search Report Jan. 28, 2013.
Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
Righetti et al, “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113.
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992).
Sanghvi, N.T., et al., “Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210.
PCT International Search Report and Written Opinion, PCT/US2014/030779, Sep. 1, 2014, 8 pages.
European Patent Office, Examination Report, EP 07814933.3, Aug. 5, 2014, 5 pages.
European Patent Office, Examination Report, EP 05798870.1, Oct. 20, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185100.4, Oct. 24, 2014, 4 pages.
European Patent Office, Examination Report, EP 10185112.9, Oct. 24, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185117.8, Oct. 24, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185120.2, Oct. 24, 2014, 4 pages.
Related Publications (1)
Number Date Country
20140243713 A1 Aug 2014 US
Provisional Applications (1)
Number Date Country
61263916 Nov 2009 US
Continuations (1)
Number Date Country
Parent 12954484 Nov 2010 US
Child 14270859 US